| DB ID | MyCo_7131 |
| Title | Comparative Analysis of the Wako β-Glucan Test and the Fungitell Assay for Diagnosis of Candidemia and Pneumocystis jirovecii Pneumonia |
| Year | 2018 |
| PMID | 29899003 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The study was approved by the ethics committee of the University of Freiburg, application numbers 105/09 and 293/11. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | Here conducted a retrospective case-control study at the University Medical Center Freiburg, Germany, a 1,600-bed tertiary care hospital. Archived serum samples (stored at 80°C) from patients with candidemia, bacteremia, negative blood cultures (BC), and PCP were tested for BDG using the FA (Associates of Cape Cod, East Falmouth, MA) and the GT (Wako Pure Chemical Industries, Osaka, Japan).The study includes serum samples from 120 candidemia and 63 Pneumocystis jirovecii pneumonia (PCP) patients. Two hundred patients with bacteremia or negative blood cultures served as candidemia control group. |
| Cohort No. | 63 |
| Age Group | None |
| P Value | p<0.001 |
| Sensitivity | 0.889 |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal diseases (IFD), like invasive candidiasis, invasive aspergillosis, and Pneumocystis jirovecii pneumonia (PCP), cause high morbidity and mortality among immunocompromised patients. Because a delay in the initiation of adequate therapy is associated with an increased mortality, it is of utmost importance to start antifungal treatment in time. However, the diagnosis and therapy of IFD are often delayed, because its clinical presentation is nonspecific and, consequently, the suspicion of treating physicians, especially in intensive care units (ICU), is low. Therefore, rapid and highly sensitive diagnostic tests are required to guide pre-emptive therapy in patients at risk. |
| Technique | Analytic |
| Analysis Method | Wako β-glucan test |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA , Wako β-glucan (Wako Pure Chemical Industries, Osaka, Japan) |
| Validation Techniques used | Wako β-glucan test |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
